Earlier, Amgen tried to stop the importation of recombinant human erythropoietin and derivatives (EPO) by filing a complaint with the International Trade Commission that is was a violation of Section 337 of the Tariff Act of 1930. Amgen charged that the imported EPO and the process by which it is produced in Europe are covered […]